Research Reports | Market Assessment
March 2014

LaunchTrends: Perjeta and Kadcyla (Breast Cancer) (US) (Wave 4) | 2014

LaunchTrends®: Perjeta and Kadcyla is a series of four post-launch syndicated reports designed to track physician perception and uptake of newly launched Perjeta (Roche/Genentech’s pertuzumab) and Kadcyla (Roche/Genentech’s ado-trastuzumab emtansine [T-DM1]).
LaunchTrends®: Perjeta and Kadcyla measures the impact of these new agents on the HER2-positive metastatic breast cancer market following launch. The study surveyed medical oncologists from the United States and conducted qualitative interviews with physicians. These reports evaluate physicians’ current awareness and perception of Perjeta and Kadcyla relative to other currently available therapies for HER2-positive metastatic breast cancer, current and anticipated usage of Perjeta and Kadcyla and promotional activity of Perjeta and Kadcyla.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports